Frederic Farid Rahbari Oskoui, MD, MS

Associate Professor of Medicine

Department of Medicine

Office: WMB 2217

Phone: 404-727-2590

Fax: 404-727-3425

Email: frahbar@emory.edu

Biography

Frederic Farid Rahbari-Oskoui, MD, MS is the director of Cystic Kidney Diseases Clinic at Emory University and a nephrologist practicing at Emory University Hospital, the Emory Clinic, and the Grady Memorial Hospital.

Dr. Rahbari attended medical school at Université de Bordeaux in France and obtained his MD (magna cum laude) in 1997 after completing a residency program in general medicine and partial nephrology training at the same institution. He worked as an attending physician in Normandy, France for two years before moving to the United States. Dr. Rhabari spent two years in clinical and translational research on oxidative stress, both at Université de Bordeaux and at New York Medical College. He subsequently redid three years of residency training in internal medicine at St. Vincent Hospital -Columbia University College of Physicians and Surgeons from 2000-2003 and completed his academic track fellowship in nephrology at Emory University from 2003-2006, including an additional year in cystic and inherited diseases of the kidneys.

He joined the faculty at Emory University School of Medicine’s Division of Renal Medicine in July of 2006 at the rank of instructor. He was named an assistant professor of medicine in 2007 and an associate professor of medicine in 2014. During this time, he also obtained a master of science in clinical research (MSCR) degree from Emory University.

Dr. Rahbari is a diplomat of the American Board of Internal Medicine and is board-certified in nephrology.

He specializes in cystic diseases of the kidneys, inherited diseases of the kidneys, hypertension, ambulatory blood-pressure monitoring, and imaging in renal diseases, and he is involved in caring for patients with kidney diseases as well as conducting research in those fields.

He has co-authored more than 50 original manuscripts, review articles, and textbook chapters and is a regular author for UpToDate on cystic diseases of the kidneys and polycystic kidney disease.

He is a Fellow of the American Society of Nephrology, a member of the Scientific Advisory Committee of the Polycystic Kidney Disease Foundation, a member of the Emory University Promotions and Tenure Committee, and a member of the HALT-PKD Trial Steering Committee and the SPRINT Trial Publication and Presentations Committee.

 He has been (and/or continues to be) an investigator in several landmark trials and observational cohorts: 

1- HALT-PKD trial: Multi-center, randomized double-blind placebo controlled trial of multi-level blockage of the RAAS by ACE-I +/- ARBs in ADPKD (2004-2014)

2- TEMPO and REPRISE trials: Safety and Efficacy of the Vasopressin receptor antagonist Tolvaptan in ADPKD (2005-present)

3- The Systolic Blood pressure trial (SPRINT trial)

4- Consortium for Radiologic Imaging of Polycystic Kidney disease: CRISP

5- MUSE trial

6- The Melatonin in night-time blood pressure in African-Americans (MAP) trials

7- Pharmacogenomics of Essential Hypertension (PEAR trial)

8- PKD cohort study: Observational cohort of ADPKD patients followed for seven years